Novo Nordisk Pays $58.65M To Settle Claim It Downplayed Victoza Cancer Risk
WASHINGTON, D.C. — Drug maker Novo Nordisk Inc. on Sept. 5 agreed to pay $58.65 million to settle federal allegations that it instructed sales representatives to downplay a federally required warning...To view the full article, register now.
Already a subscriber? Click here to view full article